Baidu
map

Oncogene:核转运蛋白β1作为脑胶质瘤治疗靶点的分子机制研究新进展

2018-04-11 佚名 上海生科院

近日,中国科学院神经科学研究所、脑科学与智能技术卓越创新中心、神经科学国家重点实验室熊志奇研究组的研究成果,以《KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells》为题,在线发表在《Oncogene》上。研究揭示了

近日,中国科学院神经科学研究所、脑科学与智能技术卓越创新中心、神经科学国家重点实验室熊志奇研究组的研究成果,以《KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells》为题,在线发表在《Oncogene》上。研究揭示了抑制蛋白核转运受体KPNB1产生蛋白稳态失调和非折叠蛋白反应(unfolded protein response, UPR),阐明了凋亡的上游分子信号通路和耐受机制,而相应的联合用药具有更好地肿瘤杀伤效果。

恶性胶质瘤是原发性恶性脑肿瘤最常见的分型,目前的常规治疗手段无显着改善作用。深入了解胶质母细胞瘤(GBM)的致病分子机制有助于发现药物靶标,开发药物和用药策略。KPNB1的表达与胶质瘤的恶性级别以及患者生存率正相关,是潜在的致病基因。KPNB1介导蛋白质的入核,也参与有丝分裂,这对肿瘤细胞的恶性增殖是必需的,故KPNB1是潜在的治疗靶标。科学家已发现抑制KPNB1可诱导肿瘤细胞凋亡,但相关分子机制尚不清楚。

在该项工作中,研究人员发现,抑制KPNB1会下调GBM细胞的生长并诱导凋亡,但不引起有丝分裂障碍。抑制KPNB1上调促凋亡Bcl-2家族蛋白Puma和Noxa,解除抗凋亡Bcl-2家族蛋白Mcl-1和Bcl-xL对凋亡的抑制。据此联用KPNB1抑制剂和Bcl-xL抑制剂能加剧凋亡。研究人员推测,KPNB1的货物蛋白众多,抑制KPNB1或引起蛋白质错误分布和蛋白稳态失调,产生应激反应。进一步研究显示,抑制KPNB1使货物蛋白NF-κB p65阻滞在细胞浆中并泛素化,促进多种分子伴侣和自噬相关蛋白与p65结合,并引起泛素化蛋白聚集,激活UPR中的PERK/eIF2α/ATF4通路,上调Puma和Noxa。这支持了上述推测。此时,细胞通过UPR减少蛋白质合成,并通过自噬和蛋白酶体途径降解蛋白质,以此缓解蛋白过载和细胞毒性,如蛋白质稳态无法恢复,过度激活的UPR即上调促凋亡Bcl-2蛋白,诱导凋亡。溶酶体或蛋白酶体抑制剂加剧蛋白过载,促进KPNB1抑制剂诱导GBM细胞凋亡。

该研究揭示了KPNB1在维持肿瘤细胞蛋白质稳态中的重要作用,系统展示了靶向KPNB1引起GBM细胞凋亡和耐受凋亡诱导的分子机制,为后续开发KPNB1抑制剂和其他抗肿瘤药联合治疗策略提供了思路和依据,为深入研究GBM的病理和治疗干预方法奠定了坚实基础。

研究工作得到中科院战略性先导科技专项、国家自然科学基金和科技部项目等的资助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696308, encodeId=d9c116963088b, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Feb 09 13:32:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895365, encodeId=346118953654f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Nov 16 20:32:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667752, encodeId=f5de166e752dd, content=<a href='/topic/show?id=533262156fb' target=_blank style='color:#2F92EE;'>#核转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62156, encryptionId=533262156fb, topicName=核转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec0026169755, createdName=hukaixun, createdTime=Tue Aug 14 14:32:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049010, encodeId=04af2049010cf, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 25 06:32:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056183, encodeId=65b12056183e9, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Oct 13 21:32:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558114, encodeId=4326155811461, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 13 10:32:00 CST 2018, time=2018-04-13, status=1, ipAttribution=)]
    2019-02-09 yzh409
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696308, encodeId=d9c116963088b, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Feb 09 13:32:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895365, encodeId=346118953654f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Nov 16 20:32:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667752, encodeId=f5de166e752dd, content=<a href='/topic/show?id=533262156fb' target=_blank style='color:#2F92EE;'>#核转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62156, encryptionId=533262156fb, topicName=核转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec0026169755, createdName=hukaixun, createdTime=Tue Aug 14 14:32:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049010, encodeId=04af2049010cf, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 25 06:32:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056183, encodeId=65b12056183e9, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Oct 13 21:32:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558114, encodeId=4326155811461, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 13 10:32:00 CST 2018, time=2018-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696308, encodeId=d9c116963088b, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Feb 09 13:32:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895365, encodeId=346118953654f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Nov 16 20:32:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667752, encodeId=f5de166e752dd, content=<a href='/topic/show?id=533262156fb' target=_blank style='color:#2F92EE;'>#核转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62156, encryptionId=533262156fb, topicName=核转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec0026169755, createdName=hukaixun, createdTime=Tue Aug 14 14:32:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049010, encodeId=04af2049010cf, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 25 06:32:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056183, encodeId=65b12056183e9, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Oct 13 21:32:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558114, encodeId=4326155811461, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 13 10:32:00 CST 2018, time=2018-04-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696308, encodeId=d9c116963088b, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Feb 09 13:32:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895365, encodeId=346118953654f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Nov 16 20:32:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667752, encodeId=f5de166e752dd, content=<a href='/topic/show?id=533262156fb' target=_blank style='color:#2F92EE;'>#核转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62156, encryptionId=533262156fb, topicName=核转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec0026169755, createdName=hukaixun, createdTime=Tue Aug 14 14:32:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049010, encodeId=04af2049010cf, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 25 06:32:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056183, encodeId=65b12056183e9, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Oct 13 21:32:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558114, encodeId=4326155811461, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 13 10:32:00 CST 2018, time=2018-04-13, status=1, ipAttribution=)]
    2018-09-25 cy0324
  5. [GetPortalCommentsPageByObjectIdResponse(id=1696308, encodeId=d9c116963088b, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Feb 09 13:32:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895365, encodeId=346118953654f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Nov 16 20:32:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667752, encodeId=f5de166e752dd, content=<a href='/topic/show?id=533262156fb' target=_blank style='color:#2F92EE;'>#核转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62156, encryptionId=533262156fb, topicName=核转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec0026169755, createdName=hukaixun, createdTime=Tue Aug 14 14:32:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049010, encodeId=04af2049010cf, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 25 06:32:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056183, encodeId=65b12056183e9, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Oct 13 21:32:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558114, encodeId=4326155811461, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 13 10:32:00 CST 2018, time=2018-04-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1696308, encodeId=d9c116963088b, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat Feb 09 13:32:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895365, encodeId=346118953654f, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Nov 16 20:32:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667752, encodeId=f5de166e752dd, content=<a href='/topic/show?id=533262156fb' target=_blank style='color:#2F92EE;'>#核转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62156, encryptionId=533262156fb, topicName=核转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec0026169755, createdName=hukaixun, createdTime=Tue Aug 14 14:32:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049010, encodeId=04af2049010cf, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Sep 25 06:32:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056183, encodeId=65b12056183e9, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Oct 13 21:32:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558114, encodeId=4326155811461, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 13 10:32:00 CST 2018, time=2018-04-13, status=1, ipAttribution=)]
    2018-04-13 zsyan
Baidu
map
Baidu
map
Baidu
map